Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDV dengue vaccine in Japanese adults, adolescents, and children
NCT06741683Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus in dengue fever, sponsored by Takeda. Started Jan 2025; status: completed.
02
Drugs
live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT06741683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06741683.